Known targets — ChEMBL curated mechanism
CSF1RFLT1FLT4KDRKITPDGFRAPDGFRB
The experimentally established mechanism targets of Vatalanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 known ✓ | P17948 | 19/20 | 0.97 |
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 9/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 8/20 | 0.97 |
| ▸ | CSF1R known ✓ | P07333 | 2/20 | 0.97 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.97 |
| ▸ | PDGFRA known ✓ | P16234 | 1/20 | 0.97 |
| ▸ | CIT | O14578 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | HLA-A | P04439 | 1/20 | 0.97 |
| ▸ | RET | P07949 | 1/20 | 0.97 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.97 |
| ▸ | FRK | P42685 | 1/20 | 0.97 |
| ▸ | CDK8 | P49336 | 1/20 | 0.97 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.97 |
| ▸ | STK3 | Q13188 | 1/20 | 0.97 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.97 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.97 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.97 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatalanib SCHEMBL29633763 | 1.00 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL905616 | 1.00 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL18286 | 0.99 | FLT1 (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL29350047 | 0.99 | FLT1 (1.00) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131019 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131018 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6131017 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL28147347 | 0.97 | FLT1 (0.97) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6605579 | 0.92 | KDR (0.88) | FLT1KDRPDGFRBKITCSF1R | |
| Vatalanib SCHEMBL6607537 | 0.91 | KDR (0.84) | FLT1KDRPDGFRBKITCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641458-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-04-05 | — | — | EP | claimed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | claimed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | claimed |
| EP-2277595-A2 | Compounds for immunopotentiation | Novartis Vaccines and Diagnostics, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| CN-101146549-A | Antiangiogenic agents and aldesleukin | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-03-19 | — | — | CN | disclosed |
| EP-1853302-A2 | ANTIANGIOGENIC AGENTS WITH ALDESLEUKIN | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-7268137-B2 | Ocular therapy | NOVARTIS AG (CH) | 2007-09-11 | — | — | US | disclosed |
| EP-1105136-B1 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | NOVARTIS AG (CH) | 2007-08-29 | — | — | EP | disclosed |
| EP-1765313-A2 | COMPOUNDS FOR IMMUNOPOTENTIATION | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002422-A9 | COMPOUNDS FOR IMMUNOPOTENTIATION | CHIRON CORP (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2003-10-09 | — | — | US | disclosed |
| US-20030171375-A1 | Method for treating ocular neovascular diseases | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
| US-6514974-B2 | 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine for example | NOVARTIS AG (CH) | 2003-02-04 | — | — | US | disclosed |
| CN-1367695-A | Phthalazine derivatives for the treatment of inflammatory diseases | NOVARTIS AG (CH) | 2002-09-04 | — | — | CN | disclosed |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | BOLD GUIDO (CH) | 2002-07-11 | — | — | US | disclosed |
| US-6271233-B1 | ADMINISTERING PHTHALAZINE DERVIVATIVES FOR TREATMENT AND PREVENTION OF RETINAL AND CHOROIDAL NEOVASCULARIZATION, EXUDATIVE AGE RELATED MACULAR DEGENERATION, PROLIFERATIVE DIABETIC RETINOPATHY, AND/OR ISCHEMIC RETINOPATHIES | CIBA VISION CORPORATION | 2001-08-07 | — | — | US | disclosed |
| US-6258812-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS AND CARDIOVASCULAR DISORDERS | NOVARTIS AG (CH) | 2001-07-10 | — | — | US | disclosed |
| EP-1105136-A2 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | Novartis AG (CH) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009098-A2 | METHOD FOR TREATING OCULAR NEOVASCULAR DISEASES | NOVARTIS AG (CH) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191129-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | FLT1 4/4885KDR 10/4885PDGFRB 124/4885 |
| US-20030171375-A1 | Method for treating ocular neovascular diseases | ALDH1A2, VEGFA, FLT4 | FLT1 5/4885KDR 4/4885PDGFRB 110/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | FLT1 2393/4885KDR 2584/4885PDGFRB 3406/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | FLT1 108/4885KDR 229/4885PDGFRB 667/4885 |
| US-20020091261-A1 | Phthalazines with angiogenesis inhibiting activity | PGF, VEGFA, FLT4 | FLT1 4/4885KDR 16/4885PDGFRB 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.